Iconovo has filed a broad patent application for inhaled GLP-1 receptor agonists, used for the treatment of obesity and type 2 diabetes. This is a rapidly growing market, and Iconovo aims to introduce a more patient-friendly alternative to today's injections.
- This marks the first step in Iconovo's new initiative to develop more convenient, reliable, and cost-effective treatments for obesity, the company stated.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/05/iconovo-initiates-development-of-inhaled-obesity-treatment/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/iconovo/r/biostock-iconovo-initiates-development-of-inhaled-obesity-treatment,c3984705

(c) 2024 Cision. All rights reserved., source Press Releases - English